David Fajgenbaum

Overview

David Fajgenbaum is presented as a physician-scientist, Castleman disease patient, and co-founder of Every Cure whose work centers on finding new disease uses for existing medicines.

Current Profile

Fajgenbaum’s research program grew from two experiences described in the episode: his mother’s death from glioblastoma and his own repeated, life-threatening relapses of Castleman disease. After standard and experimental treatments failed to hold remission, he collected longitudinal samples, compared immune and serum signals, examined lymph-node tissue, and formed a hypothesis around mTOR activation. With physician involvement, he began sirolimus—then approved for transplant rejection—and reports a remission lasting more than eleven years at recording.

The durable contribution is not the claim that one patient’s self-study can establish a treatment. Fajgenbaum instead turns the case into an organizational method: mobilize patients and experts, map existing evidence, prioritize plausible drug-disease matches, test them, and disseminate results. His public stance combines urgency and agency with a repeated validation boundary around laboratory work, trials, observational evidence, expert review, and prescribing decisions made by clinicians and patients.

Key Characteristics

• Combines lived rare-disease experience with medical research and organizational strategy.
• Uses longitudinal samples and mechanistic investigation to generate treatment hypotheses.
• Treats patient agency as active participation in expert networks, not substitution for physicians.
• Focuses on drug repurposing where approved medicines and unmet diseases may be poorly connected.
• Emphasizes evidence escalation from computational or case signals to laboratory and clinical validation.
• Frames hope as useful when it drives action that can produce observable impact.

Evidence

• Personal disease course and hypothesis formation - Using Existing Drugs in New Ways to Treat & Cure Diseases of Brain & Body | Dr. David Fajgenbaum describes repeated Castleman relapses, stored samples, mTOR findings, physician-prescribed sirolimus, and reported long remission.
• Institution building - Using Existing Drugs in New Ways to Treat & Cure Diseases of Brain & Body | Dr. David Fajgenbaum connects the Castleman research network to the later all-drug, all-disease ambition of Every Cure.
• Safety and evidence posture - Using Existing Drugs in New Ways to Treat & Cure Diseases of Brain & Body | Dr. David Fajgenbaum says promising matches should pass laboratory, trial, observational, and expert review before physician-patient prescribing decisions.

Qualifications

The current profile rests on one public podcast summary and Fajgenbaum’s account. It does not independently verify diagnoses, mechanisms, treatment history, remission duration, organizational results, or the generalizability of any case. Self-measurement can produce hypotheses but cannot by itself establish causality, population efficacy, dose, or safety.

What Changed

• Established Fajgenbaum’s profile as a patient, physician-scientist, and drug-repurposing institution builder.
• Distinguished his personal sirolimus experience from the evidence needed for general clinical use.

Relationships

• Every Cure - co-founded nonprofit scaling his drug-repurposing method.
• Castleman Disease - illness that motivated his research and patient-organizing work.
• Drug Repurposing - principal research and systems strategy.
• Patient-Led Rare-Disease Infrastructure / 患者主导的罕见病基础设施 - organizational model linking patients, specialists, samples, and research priorities.
• Self-Experimentation - adjacent practice bounded by the limits of single-person evidence.
• Huberman Lab - interview venue for the current source.